Restricted accessResearch articleFirst published online 2014-07
Transgenic Expression of Human Glial Cell Line-Derived Neurotrophic Factor from Integration-Deficient Lentiviral Vectors is Neuroprotective in a Rodent Model of Parkinson's Disease
Standard integration-proficient lentiviral vectors (IPLVs) are effective at much lower doses than other vector systems and have shown promise for gene therapy of Parkinson's disease (PD). Their main drawback is the risk of insertional mutagenesis. The novel biosafety-enhanced integration-deficient lentiviral vectors (IDLVs) may offer a significant enhancement in biosafety, but have not been previously tested in a model of a major disease. We have assessed biosafety and transduction efficiency of IDLVs in a rat model of PD, using IPLVs as a reference. Genomic insertion of lentivectors injected into the lesioned striatum was studied by linear amplification-mediated polymerase chain reaction (PCR), followed by deep sequencing and insertion site analysis, demonstrating lack of significant IDLV integration. Reporter gene expression studies showed efficient, long-lived, and transcriptionally targeted expression from IDLVs injected ahead of lesioning in the rat striatum, although at somewhat lower expression levels than from IPLVs. Transgenic human glial cell line-derived neurotrophic factor (hGDNF) expression from IDLVs was used for a long-term investigation of lentivector-mediated, transcriptionally targeted neuroprotection in this PD rat model. Vectors were injected before striatal lesioning, and the results showed improvements in nigral dopaminergic neuron survival and behavioral tests regardless of lentiviral integration proficiency, although they confirmed lower expression levels of hGDNF from IDLVs. These data demonstrate the effectiveness of IDLVs in a model of a major disease and indicate that these vectors could provide long-term PD treatment at low dose, combining efficacy and biosafety for targeted central nervous system applications.
Get full access to this article
View all access options for this article.
References
1.
Abordo-AdesidaE., FollenziA., BarciaC., et al. (2005). Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther., 16, 741–751.
2.
AiutiA., BiascoL., ScaramuzzaS., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.
3.
ApoloniaL., WaddingtonS.N., FernandesC., et al. (2007). Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol. Ther., 15, 1947–1954.
4.
ArensA., AppeltJ.U., BartholomaeC., et al. (2012). Bioinformatical clonality analysis of next generation sequencing derived viral vector integration sites. Hum. Gene Ther. Methods., 23, 111–118.
5.
BanasikM.B., and McCrayP.B.Jr. (2010). Integrase-defective lentiviral vectors: progress and applications. Gene Ther., 17, 150–157.
6.
BartusR.T., BrownL., WilsonA., et al. (2011). Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol. Disease, 44, 38–52.
7.
BatchelorP.E., LiberatoreG.T., WongJ.Y., et al. (1999). Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci., 19, 1708–1716.
8.
BiascoL., BaricordiC., and AiutiA. (2012). Retroviral integrations in gene therapy trials. Mol. Ther., 20, 709–716.
9.
BiffiA., BartolomaeC.C., CesanaD., et al. (2011). Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood, 117, 5332–5339.
10.
BjorklundA., KirikD., RosenbladC., et al. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res., 886, 82–98.
11.
BroadstockM., and Yáñez-MuñozR.J. (2012). Challenges for gene therapy of CNS disorders and implications for Parkinson's disease therapies. Hum. Gene Ther., 23, 340–343.
12.
CannonJ.R., SewT., MonteroL., et al. (2011). Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp. Neurol., 228, 41–52.
13.
ChenQ., HeY., and YangK. (2005). Gene therapy for Parkinson's disease: progress and challenges. Curr. Gene Ther., 5, 71–80.
14.
ChickH.E., NowrouziA., FronzaR., et al. (2012). Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Hum. Gene Ther., 23, 1247–1257.
15.
CiesielskaA., MittermeyerG., HadaczekP., et al. (2011). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther., 19, 922–927.
16.
CockrellA.S., and KafriT. (2007). Gene delivery by lentivirus vectors. Mol. Biotechnol., 36, 184–204.
17.
CohenA.D., ZigmondM.J., and SmithA.D. (2011). Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res., 1370, 80–88.
18.
CondiottiR., GoldenbergD., GiladiH., et al. (2013). Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature. Mol. Ther., 22, 59–68.
19.
DrinkutA., TereshchenkoY., SchulzJ.B., et al. (2012). Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol. Ther., 20, 534–543.
20.
DullT., ZuffereyR., KellyM., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol., 72, 8463–8471.
21.
EslamboliA., CummingsR.M., RidleyR.M., et al. (2003). Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol., 184, 536–548.
22.
GeorgievskaB., KirikD., and BjorklundA. (2004). Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci., 24, 6437–6445.
23.
GillS.S., PatelN.K., HottonG.R., et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 9, 589–595.
24.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348, 255–256.
25.
HeftiF., MelamedE., SahakianB.J., and WurtmanR.J. (1980). Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol. Biochem. Behav., 12, 185–188.
26.
HiokiH., KamedaH., NakamuraH., et al. (2007). Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters. Gene Ther., 14, 872–882.
27.
HutsonT.H., VerhaagenJ., Yáñez-MuñozR.J., and MoonL.D. (2012). Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther., 19, 49–60.
28.
JakobssonJ., and LundbergC. (2006). Lentiviral vectors for use in the central nervous system. Mol. Ther., 13, 484–493.
29.
JakobssonJ., EricsonC., JanssonM., et al. (2003). Targeted transgene expression in rat brain using lentiviral vectors. J. Neurosci. Res., 73, 876–885.
30.
KirikD., RosenbladC., and BjorklundA. (2000). Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci., 12, 3871–3882.
31.
LangA.E., GillS., PatelN.K., et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 59, 459–466.
32.
LiM., HusicN., LinY., et al. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J. Neurosci. Methods, 189, 56–64.
33.
LinL.F., DohertyD.H., LileJ.D., et al. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260, 1130–1132.
34.
LyonsK.E., and PahwaR. (2011). Diagnosis and initiation of treatment in Parkinson's disease. Int. J. Neurosci., 121Suppl 2, 27–36.
35.
MarksW.J.Jr., OstremJ.L., VerhagenL., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol., 7, 400–408.
36.
MarksW.J.Jr., BartusR.T., SiffertJ., et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 9, 1164–1172.
37.
MátraiJ., ChuahM.K., and VandendriesscheT. (2010). Recent advances in lentiviral vector development and applications. Mol. Ther., 18, 477–490.
38.
MátraiJ., CantoreA., BartholomaeC.C., et al. (2011). Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology, 53, 1696–1707.
39.
MirzaB., HadbergH., ThomsenP., and MoosT. (2000). The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience, 95, 425–432.
40.
MogiM., TogariA., KondoT., et al. (2001). Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci. Lett., 300, 179–181.
41.
NowrouziA., CheungW.T., LiT., et al. (2013). The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis. Mol. Ther., 21, 324–337.
42.
ParuzynskiA., ArensA., GabrielR., et al. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc., 5, 1379–1395.
43.
PascualA., Hidalgo-FigueroaM., PiruatJ.I., et al. (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci., 11, 755–761.
44.
PeluffoH., FosterE., AhmedS.G., et al. (2013). Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord. Gene Ther., 20, 645–657.
45.
PhilippeS., SarkisC., BarkatsM., et al. (2006). Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 103, 17684–17689.
46.
RahimA.A., WongA.M., HoweS.J., et al. (2009). Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther., 16, 509–520.
47.
RichardsonR.M., KellsA.P., RosenbluthK.H., et al. (2011). Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol. Ther., 19, 1048–1057.
48.
SaavedraA., BaltazarG., and DuarteE.P. (2008). Driving GDNF expression: the green and the red traffic lights. Prog. Neurobiol., 86, 186–215.
49.
SchmidtM., SchwarzwaelderK., BartholomaeC., et al. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods, 4, 1051–1057.
50.
StanicD., ParishC.L., ZhuW.M., et al. (2003). Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J. Neurochem., 86, 329–343.
51.
ThemisM., WaddingtonS.N., SchmidtM., et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther., 12, 763–771.
52.
TomacA., WidenfalkJ., LinL.F., et al. (1995). Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. USA, 92, 8274–8278.
53.
TothG., YangH., AnguelovR.A., et al. (2002). Gene transfer of glial cell-derived neurotrophic factor and cardiotrophin-1 protects PC12 cells from injury: involvement of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase pathways. J.Neurosci. Res., 69, 622–632.
54.
WanischK., and Yáñez-MuñozR.J. (2009). Integration-deficient lentiviral vectors: a slow coming of age. Mol. Ther., 17, 1316–1332.
55.
Yáñez-MuñozR.J., BalagganK.S., MacneilA., et al. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med., 12, 348–353.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
